We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

41 hedge funds and large institutions have $6.86M invested in AIM ImmunoTech in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

14% more funds holding

Funds holding: 36 → 41 (+5)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

53% less capital invested

Capital invested by funds: $14.7M → $6.86M (-$7.88M)

Holders
41
Holders Change
+5
Holders Change %
+13.89%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
6
Reduced
10
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$1.09M
2
Citadel Advisors
Citadel Advisors
Florida
+$63.6K
3
VF
Virtu Financial
New York
+$58.3K
4
Jane Street
Jane Street
New York
+$24K
5
Verition Fund Management
Verition Fund Management
Connecticut
+$21K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$531K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$107K
3
WG
Winton Group
United Kingdom
-$103K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$94K
5
Millennium Management
Millennium Management
New York
-$64K
Name Holding Trade Value Shares
Change 		Change in
Stake
CB
26
Community Bank
New York
$12K – – –
SSA
27
Schonfeld Strategic Advisors
New York
$10K -$155 -1 -0.9%
TCM
28
Traynor Capital Management
Pennsylvania
$10K – – –
Wells Fargo
29
Wells Fargo
California
$10K +$1.55K +10 +9%
SFG
30
SNS Financial Group
Minnesota
$9K – – –
TRCT
31
Tower Research Capital (TRC)
New York
$4K +$7.58K +49 New
Osaic Holdings
32
Osaic Holdings
Arizona
$3K +$3.09K +20 +133%
SC
33
Stephens Consulting
Michigan
$2.76K +$4.64K +30 New
JP Morgan Chase
34
JP Morgan Chase
New York
$2K – – –
HR
35
Howe & Rusling
New York
$1K – – –
HI
36
Hoey Investments
Pennsylvania
$1K +$1.55K +10 New
TWC
37
TD Waterhouse Canada
Ontario, Canada
$220 +$309 +2 New
APA
38
American Portfolios Advisors
New York
$210 – – –
Cambridge Investment Research Advisors
39
Cambridge Investment Research Advisors
Iowa
– -$94K -467 Closed
AWA
40
Arkadios Wealth Advisors
Georgia
– -$43K -216 Closed
AGM
41
Alpine Global Management
New York
– -$38K -188 Closed
Qube Research & Technologies (QRT)
42
Qube Research & Technologies (QRT)
United Kingdom
– -$32K -158 Closed
Fidelity Investments
43
Fidelity Investments
Massachusetts
– +$155 +1 New
1
2

AIM Hedge Fund Activity: Q4 2021 in Review

41 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2021, worth a combined $6.86M — down 53% from $14.7M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new AIM positions and 4 closed out — a net gain of 5 holders — while 6 added to existing stakes and 10 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.09M. The largest seller was Morgan Stanley, cutting an estimated $531K.

  • 41 institutional investors held AIM ImmunoTech (AIM) as of Q4 2021, up from 36 in Q3 2021.
  • Funds reported $6.86M of AIM ImmunoTech stock for Q4 2021, down 53% quarter-over-quarter.
  • 9 funds opened new AIM ImmunoTech positions in Q4 2021 and 4 closed out, a net change of +5 holders.
  • The largest AIM ImmunoTech buyer in Q4 2021 was Renaissance Technologies, an estimated $1.09M added.
  • The largest AIM ImmunoTech seller in Q4 2021 was Morgan Stanley, an estimated $531K sold.

Based on aggregated 13F filings for Q4 2021.